Skip to main content

Table 5 Indication-specific cumulative success rates

From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

 Latest CVD (%)Latest endo/meta (%)Generic (%)
Registration to market565690
Phase III to market34.7230.2455.80
Phase II to market14.9312.120.09
Phase I to market6.876.311.96
Preclinical to market4.263.97.41
Discovery to market2.131.953.71
  1. Cumulative success rates to market from specific stages of intervention development calculated from Table 4